The potential of contemporary diagnostic imaging modalities for improving assessment of treatment response in patients with locally advanced cervical cancer

1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ Радиологии» Минздрава России, 2019. 255 с. [Kaprin A.D., Starinsky V.V., Petrova G.V. Status of cancer care for the population of Russia in 2018. Moscow: P. Herzen Moscow Oncology Research Institute–Branch of FSBI NMRRC of the Ministry of Health of the Russian Federation, 2019: 255 p. (in Russian)].
2. Смирнов Ю.А., Богачева Т.М., Валеев Р.Г. Ультразвуковая диагностика в оценке местной распространенности рака шейки матки. Казанский медицинский журнал. 2012; 93(5): 735–8. [Smirnov Y.A., Bogacheva T.M., Valeev R.G. Ultrasonography in assessing the cervical cancer extent. Kazanskiy meditsinskiy zhurnal. 2012; 93(5): 735–8. (in Russian)].
3. Itoh N., Sawairi M., Hanabayashi T., Mori H., Yamawaki Y., Tamaya T. Neoadjuvant intraarterial infusion chemotherapy with a combination of mitomycin-c, vincristine, and cisplatin for locally advanced cervical cancer: a preliminary report. Gynecol Oncol. 1992; 47(3): 391–4. doi: 10.1016/0090-8258(92)90146-a
4. Рерберг А.Г., Каприн А.Д., Костин А.А., Новикова Е.Г., Волченко Н.Н., Чулкова О.В., Болотина Л.В., Мухтарулина С.В., Хохриков Г.И., Сидоров Д.Ю., Геворкян А.Р. Неоадъювантная комбинированная химиотерапия местнораспространенного рака шейки матки. Онкология. Журнал имени П.А. Герцена. 2017; 6(6): 32–7. [Rerberg A.G., Kaprin A.D., Kostin A.A., Novikova E.G., Volchenko N.N., Chulkova O.V., Bolotina L.V., Mukhtarullina S.V., Khokhrikov G.I., Sidorov D.Yu., Gevorkyan A.R. Neoadjuvant combined chemotherapy for locally advanced carcinoma of the cervix uteri. P.A. Herzen Journal of Oncology = Onkologiya. Zhurnal imeni P.A. Gertsena. 2017; 6(6): 32–37. (in Russian)]. doi:10.17116/onkolog20176632-37
5. Scarabelli C., Zarrelli A., Gallo A., Visentin M.C. Multimodal treatment with neoadjuvant intraarterial chemotherapy and radical surgery in patients with stage iiib-iva cervical cancer. A preliminary study. Cancer. 1995; 76(6): 1019–26. doi: 10.1002/1097-0142(19950915)76:6<1019::aid-cncr2820760616>3.0.co;2-4
6. Ishikawa H, Kikkawa F, Tamakoshi K, Matsuzawa K, Kawai M, Suganuma N, Tomoda Y. Distribution of platinum in human gynecologic tissues and lymph nodes after intravenous and intraarterial neoadjuvant chemotherapy. Anticancer Res. 1996; 16(6b): 3849–53. PMID: 9042269
7. Fujiwaki R., Iida K., Ohnishi Y., Watanabe Y., Ryuko K., Takahashi K., Miyazaki K. Intra-arterial neoadjuvant chemotherapy followed by radical surgery and radiotherapy for stage iib cervical carcinoma. Anticancer res. 1997; 17(5b): 3751–5. PMID: 9427774
8. Sugiyama T., Nishida T., Hasuo Y., Fujiyoshi K., Yakushiji M. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer. Gynecol Oncol. 1998; 69(2): 130–6. doi: 10.1006/gyno.1998.4976
9. Вишневская Е.Е., Косенко И.А. Отдаленные результаты комплексной терапии больных раком шейки матки с неблагоприятным прогнозом. Вопросы онкологии. 1999; 45(4): 420–3. [Vishnevskaya E.E., Kosenko I.A. Long-term results of comprehensive treatment for cervical cancer with poor prognosis. Voprosy onkologii. 1999; 45(4): 420–3.(In Russ.)].
10. Usuki N., Hirokawa K., Tashiro T., Saiwai S., Miyamoto T. Intraarterial chemotherapy for uterine cervical adenocarcinoma: evaluation of its efficacy as neoadjuvant therapy. Nihon Igaku Hoshasen Gakkai Zasshi. 1999; 59(12): 670–3. [Article in Japanese]. PMID: 10565169
11. Therasse P., Eisenhauer E.A., Verweij J. RECIST revisited: a review of validation studies on tumour assessment.Eur J Cancer. 2006; 8: 1031–9. doi: 10.1016/j.ejca.2006.01.026
12. Halappa V.G., Corona-Villalobos C.P., Bonekamp S., Li Z., Reyes D.K., Cosgrove D., et al. Neuroendocrine Liver Metastasis Treated by Using Intraarterial Therapy: Volumetric Functional Imaging Biomarkers of Early Tumor Response and Survival. Radiology. 2013; 266(2): 502–513. https://doi.org/10.1148/radiol.12120495
13. Sousa J.P.L.B.A, Bekhor D., Saito Filho C.F.S., Bretas E.A.S., D'lppolito G. Abdominal perfusion computed tomography: clinical applications, principles and Technique. Radiol Bras. 2012; 45: 39–45.
14. Sugiyama T., Nishida T., Hasuo Y., Fujiyoshi K., Yakushiji M. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer. Gynecol Oncol. 1998; 69(2): 130–6. doi: 10.1006/gyno.1998.4976
15. Kim S., Kamaya A., Willmann J.C.T. Perfusion of the Liver: Principles and Applications in Oncology. Radiology. 2014; 272(2): 322–44. doi: 10.1148/radiol.14130091.
16. Axel L. Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. Radiology. 1980; 137(3): 679–86. doi: 10.1148/radiology.137.3.7003648.
17. Корниенко В.Н., Пронин И.Н., Пьяных О.С., Фадеева Л.М. Исследование тканевой перфузии головного мозга методом компьютерной томографии. Медицинская визуализация. 2007; 2: 70–81. [Kornienko V.N., Pronin I.N., P’yanykh I.S., Fadeeva L.M. Issledovanie tkanevoi perfuzii golovnogo mozga metodom komp’yuternoi tomografii. Meditsinskaya vizualizatsiya. 2007; (2): 70–81. (In Russ.)].
18. Miles K., Hayball M., Dixon A. Functional images of hepatic perfusion obtained with dynamic CT. Radiology. 1993; 188(2): 405–11. doi: 10.1148/radiology.188.2.8327686
19. Долгушин М.Б., Пронин И.Н., Корниенко В.Н., и др. КТ-перфузия в оценке эффективности лучевой терапии метастатического поражения головного мозга. Медицинская физика. 2008; 2(38): 40–52. [Dolgushin M.B., Pronin I.N., Kornienko V.N., et al. Perfusion computed tomography in assessment of radiotherapy efficacy in patients with secondary brain tumors. Meditsinskaya fizika/Medical physics. 2008; 2(38): 40–52. (In Russ.)].
20. Журавлева М., Шершевер А.С., Трофимова Т.Н. Возможности перфузионной КТ в оценке результатов комбинированного и комплексного лечения глиом головного мозга. Уральский медицинский журнал. 2012; 4 (96): 81–4. [Zhuravlevа M.A., Shershever A.S., Trofimova T.N. Perfusion possibilities in evaluation brain gliomas combined and complex treatment results. Ural’skiy meditsinskiy zhurnal/Ural Medical Journal. 2012; 4 (96): 81–4. (In Russ.)].
21. Аптаев Ч., Жолдыбай Ж.Ж., Жакенова Ж.К., Ахметова Г.С., Захырова Х. Перфузионная компьютерная томография в диагностике и оценке эффективности лечения рака желудка. Онкология и радиология Казахстана. 2018; 2(48). 41–4. [Aptaev Ch., Zholdybay Zh.Zh., Zhakenova Zh.K., Akhmetova G.S., Zakhyrova Kh. Perfusion computed tomography in gastric cancer diagnostics and treatment efficacy evaluation (literature review). Onkologiya i radiologiya Kazakhstana. 2018; 2(48). 41–4. (In Russ.)].doi: 10.1016/j.tranon.2014.07.005
22. Cuneo K. C., Chenevert T. L., Ben-Josef E. et al. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol. 2014; 7(5): 644-649. doi: 10.1016/j.tranon.2014.07.005.
23. Nakao A., Kasuya H., Sahin T.T., et al. A phase I doseescalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Therapy. 2011; 18: 167–75. doi: 10.1038/cgt.2010.65
24. Shibuya K., Tsushima Y., Horisoko E., Noda S.E., Taketomi-Takahashi A., Ohno T., Amanuma M., Endo K., Nakano T.J. Blood flow change quantification in cervical cancer before and during radiation therapy using perfusion CT. Radiat Res. 2011; 52(6): 804–11. Epub 2011 Sep 30.
25. Liu J., Fan H., Qiu G.P., Int J. Vascular permeability determined using multi-slice spiral CT perfusion can predict response to chemoradiotherapy in patients with advanced cervical squamous cell carcinoma. Clin Pharmacol Ther. 2017; 55(7): 619–26. doi: 10.5414/CP202847.
26. Li X.S., Fan H.X., Zhu H.X., Song Y.L., Zhou C.W. The value of perfusion CT in predicting the short-term response to synchronous radiochemotherapy for cervical squamous cancer. Eur Radiol. 2012; 22(3): 617–24. doi: 10.1007/s00330-011-2280-6.
27. Magné N., Chargari C., Vicenzi L., et al. New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET. Cancer Treat. Rev. 2008; 34(8): 671–81. doi: 10.1016/j.ctrv.2008.08.003.
28. Grigsby P., Siegel B., Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001; 19(17): 3745–9. DOI: 10.1200/JCO.2001.19.17.3745
29. Wong T., Jones E., Coleman R., et al. Positron emission tomography with 2-deoxy-2- 18 [F]uoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol. Imaging Bio. 2004; 6(1): 55–62. doi: 10.1006/gyno.1993.1268
30. Chu Y., Zheng A., Wang F., et al. Diagnostic value of F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. Nucl Med Commun. 2014; 35(2): 144–150. doi: 10.1097/MNM.0000000000000026.
31. Brooks R., Rader J., Dehdashti F., et al. Surveillance FDG-PET detectionof asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009; 112(1): 104–9. doi: 10.1016/j.ygyno.2008.08.028
32. Scottish Intercollegiate Guidelines Network. Management of cervical cancer/ (SIGN guideline no 99). 2008.
33. National Comprehensive Cancer Network (NCCN) guidelines for cervical cancer. 2017.
34. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using 18-Fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999; 35(13): 1773–82. doi: 10.1016/s0959-8049(99)00229-4
35. Wang X., Koch S. Positron emission tomography/computed tomography potential pitfalls and artifacts. Curr Probl Diagn Radiol. 2009; 38(4): 156–69. doi: 10.1067/j.cpradiol.2008.01.001.
36. Amit A., Person O., Keidar Z. FDG PET/CT in monitoring response to treatment in gynecological malignancies. Curr Opin Obstet Gynecol. 2013; 25(1):17–22. http://dx.doi.org/10.1097/GCO.0b013e32835a7e96
37. Young H., Baum R., Cremerius U., at all. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999; 35(13): 1773–82. doi: 10.1016/s0959-8049(99)00229-4
38. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50 Suppl 1:122S–50S. doi: 10.2967/jnumed.108.057307.
39. Schwarz J., Grigsby P., Dehdashti F., et al. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med. 2009; 50(1): 64S-73S. doi: 10.2967/jnumed.108.057257.
40. Grigsby P., Siegel B., Dehdashti F., et al. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004; 22(11): 2167–71. doi: 10.1200/JCO.2004.09.035
41. Avril N., Sassen S., Schmalfeldt B., et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005; 23(30):7445–53. doi: 10.1200/JCO.2005.06.965
42. Banks T.I., von Eyben R., Hristov D., Kidd E.A. Pilot study of combined FDG-PET and dynamic contrast-enhanced CT of locally advanced cervical carcinoma before and during concurrent chemoradiotherapy suggests association between changes in tumor blood volume and treatment response. Cancer Med. 2018; 7(8): 3642–51. doi: 10.1002/cam4.1632.

Received 26.12.2019

Accepted 09.01.2020